Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
Scenic Biotech has raised $31.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Scenic Biotech's investors include Oxford Science Enterprises, Inkef, BioMedPartners, EIR Ventures, BioGeneration Ventures.
Scenic Biotech is headquartered in Amsterdam, The Netherlands.
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
Scenic Biotech is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scenic Biotech — Funding & Investors." VCBacked, March 9, 2022, https://www.vcbacked.co/company/scenic-biotech. Accessed September 29, 2026.
VCBacked. (2022). Scenic Biotech — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/scenic-biotech
{{cite web |title=Scenic Biotech — Funding & Investors |url=https://www.vcbacked.co/company/scenic-biotech |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated